Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
GET POWR RATINGS... FREE!
WVE POWR Grades
- Sentiment is the dimension where WVE ranks best; there it ranks ahead of 90.62% of US stocks.
- WVE's strongest trending metric is Growth; it's been moving down over the last 177 days.
- WVE ranks lowest in Stability; there it ranks in the 24th percentile.
WVE Stock Summary
- WVE's price/sales ratio is 88.46; that's higher than the P/S ratio of 97.5% of US stocks.
- WVE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.37% of US stocks.
- Revenue growth over the past 12 months for WAVE LIFE SCIENCES LTD comes in at -91.42%, a number that bests merely 1.27% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to WAVE LIFE SCIENCES LTD, a group of peers worth examining would be MCRB, CDAK, CRIS, FIXX, and VXRT.
- WVE's SEC filings can be seen here. And to visit WAVE LIFE SCIENCES LTD's official web site, go to www.wavelifesciences.com.
WVE Valuation Summary
- In comparison to the median Healthcare stock, WVE's price/earnings ratio is 110.26% lower, now standing at -2.4.
- Over the past 86 months, WVE's EV/EBIT ratio has gone up 18.3.
Below are key valuation metrics over time for WVE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| WVE | 2022-12-02 | 87.4 | -80.8 | -2.4 | -2.0 |
| WVE | 2022-12-01 | 90.5 | -83.6 | -2.5 | -2.1 |
| WVE | 2022-11-30 | 88.3 | -81.5 | -2.4 | -2.0 |
| WVE | 2022-11-29 | 85.1 | -78.6 | -2.3 | -1.9 |
| WVE | 2022-11-28 | 93.0 | -85.9 | -2.5 | -2.2 |
| WVE | 2022-11-25 | 88.3 | -81.5 | -2.4 | -2.0 |
WVE Growth Metrics
- Its 4 year revenue growth rate is now at 1052.73%.
- Its 5 year cash and equivalents growth rate is now at -21.41%.
- Its 2 year revenue growth rate is now at 149.53%.
The table below shows WVE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 40.313 | -103.912 | -120.125 |
| 2022-03-31 | 42.714 | -84.491 | -117.595 |
| 2021-12-31 | 40.964 | -88.993 | -122.245 |
| 2021-09-30 | 48.638 | -113.375 | -116.249 |
| 2021-06-30 | 15.665 | -105.363 | -143.119 |
| 2021-03-31 | 15.916 | -134.107 | -144.881 |
WVE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- WVE has a Quality Grade of C, ranking ahead of 33.55% of graded US stocks.
- WVE's asset turnover comes in at 0.06 -- ranking 311th of 680 Pharmaceutical Products stocks.
- IONS, CORT, and CPIX are the stocks whose asset turnover ratios are most correlated with WVE.
The table below shows WVE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.060 | 1 | -4.284 |
| 2021-03-31 | 0.061 | 1 | -4.798 |
| 2020-12-31 | 0.078 | 1 | -7.715 |
| 2020-09-30 | 0.050 | 1 | -5.619 |
| 2020-06-30 | 0.047 | 1 | -5.196 |
| 2020-03-31 | 0.055 | 1 | -4.843 |
WVE Price Target
For more insight on analysts targets of WVE, see our WVE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.86 | Average Broker Recommendation | 1.64 (Moderate Buy) |
WVE Stock Price Chart Interactive Chart >
WVE Price/Volume Stats
| Current price | $4.39 | 52-week high | $5.31 |
| Prev. close | $4.25 | 52-week low | $1.16 |
| Day low | $4.09 | Volume | 672,600 |
| Day high | $4.41 | Avg. volume | 419,712 |
| 50-day MA | $4.24 | Dividend yield | N/A |
| 200-day MA | $2.97 | Market Cap | 381.50M |
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
Latest WVE News From Around the Web
Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.
H.C. Wainwright Reaffirms Their Buy Rating on Wave Life Sciences (WVE)H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Wave Life Sciences (WVE - Research Report) today and set a price target of $8.00. The company's shares closed yesterday at $4.17.Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Unity Biotechnology, and Matinas BioPharma. According to TipRanks, Fein has an average return of -11.0% and a 34.58% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Wave Life Sciences with a $10.50 average price target, implying a 151.80% upside from current levels. |
Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Ayr Wellness (AYRWF)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE – Research Report), Ayr Wellness (AYRWF – Research Report) and Nkarta (NKTX – Research Report) with bullish sentiments. Wave Life Sciences (WVE) Mizuho Securities analyst Salim Syed maintained a Buy rating on Wave Life Sciences today and set a price target of $13.00. The company's shares closed last Thursday at $4.08. According to TipRanks. |
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue EstimatesWave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateAnnounced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CSF Multidosing underway in Phase 1b/2a trial of WVE-N531 in boys with DMD amenable to exon 53 skipping; muscle biopsy data from initial cohort on track for 4Q 2022 Selected WVE-006 (Wave’s first RNA editing candidate) as development candidate for AATD with CTA submissions expected in 2023 Preclinical |
Wave Life Sciences to Present at the Stifel 2022 Healthcare ConferenceCAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on Wednesday, November 16, 2022, at 3:35 p.m. ET. A live webcast of this pre |
WVE Price Returns
| 1-mo | 0.00% |
| 3-mo | 45.85% |
| 6-mo | 104.19% |
| 1-year | 19.95% |
| 3-year | -86.43% |
| 5-year | -88.07% |
| YTD | 39.81% |
| 2021 | -60.10% |
| 2020 | -1.81% |
| 2019 | -80.93% |
| 2018 | 19.77% |
| 2017 | 34.23% |
Continue Researching WVE
Want to see what other sources are saying about Wave Life Sciences Ltd's financials and stock price? Try the links below:Wave Life Sciences Ltd (WVE) Stock Price | Nasdaq
Wave Life Sciences Ltd (WVE) Stock Quote, History and News - Yahoo Finance
Wave Life Sciences Ltd (WVE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...